Fibrosis and Tissue Repair Mechanics to Therapeutics 20Q6

Web Desc
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches joint with Stromal Cells in Immunity and Disease Organizer(s): Shannon J. Turley and Thomas A. Wynn Date: February 19 - 23, 2020 Location: Fairmont Empress Victoria / Victoria Conference Centre, Victoria, BC, Canada Sponsored by Akebia Therapeutics, Genentech, Inc., Merck & Co., Inc., Novartis Institutes for BioMedical Research and Novo Nordisk A/S Summary of Meeting: Fibrosis is an important cause of morbidity and mortality worldwide. Fibrotic scarring can affect most tissues and organ systems, lead to destruction of organ architecture and loss of function. Fibrosis is a major pathogenic feature of many chronic inflammatory diseases, including interstitial lung disease, nonalcoholic steatohepatitis (NASH), glomerulonephritis, heart disease, Crohn’s disease, and systemic sclerosis. Fibrotic tissue remodeling also influences cancer metastasis and cancer therapy. Recent advances have provided a deeper understanding of the pathogenesis of fibrosis and revealed novel targets for drugs that are now at various stages of clinical development. This will be the 7th Keystone Symposium on Fibrosis, the first of which took place in 2007, and is intended to be the premier international meeting for anyone with an interest in fibrosis. The conference draws a broad swath of researchers from various disciplines, including epithelial biology, vascular biology, cancer, stem and tissue progenitor cell biology, tissue repair and regeneration, as well as those with disease-specific interests. Finally, this conference is being paired with another Keystone Symposia conference on Stromal Cells in Immunity and Disease. Hosting these two conferences in tandem will bring together academic, clinical, and translational researchers to discuss the core mechanisms driving inflammation and fibrosis, compare and contrast fibrotic diseases of different organs, discuss the best preclinical models, and debate emerging therapies. Scholarship Deadline: October 17 2019 Discounted Abstract Deadline: October 17 2019 Abstract Deadline: November 20 2019 Discounted Registration Deadline: December 18 2019 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Genentech, Inc. Pfizer Inc. Pliant Therapeutics We gratefully acknowledge the generous grant for this conference provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant No. 1 R13 DK125002-01 Funding for this conference was made possible (in part) by 1 R13 DK125002-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches

joint with Stromal Cells in Immunity and Disease

Organizer(s): Shannon J. Turley and Thomas A. Wynn

Date: February 19 - 23, 2020
Location: Fairmont Empress Victoria / Victoria Conference Centre, Victoria, BC, Canada

Sponsored by Akebia Therapeutics, Genentech, Inc., Merck & Co., Inc., Novartis Institutes for BioMedical Research and Novo Nordisk A/S

Summary of Meeting:

Fibrosis is an important cause of morbidity and mortality worldwide. Fibrotic scarring can affect most tissues and organ systems, lead to destruction of organ architecture and loss of function. Fibrosis is a major pathogenic feature of many chronic inflammatory diseases, including interstitial lung disease, nonalcoholic steatohepatitis (NASH), glomerulonephritis, heart disease, Crohn’s disease, and systemic sclerosis. Fibrotic tissue remodeling also influences cancer metastasis and cancer therapy. Recent advances have provided a deeper understanding of the pathogenesis of fibrosis and revealed novel targets for drugs that are now at various stages of clinical development. This will be the 7th Keystone Symposium on Fibrosis, the first of which took place in 2007, and is intended to be the premier international meeting for anyone with an interest in fibrosis. The conference draws a broad swath of researchers from various disciplines, including epithelial biology, vascular biology, cancer, stem and tissue progenitor cell biology, tissue repair and regeneration, as well as those with disease-specific interests. Finally, this conference is being paired with another Keystone Symposia conference on Stromal Cells in Immunity and Disease. Hosting these two conferences in tandem will bring together academic, clinical, and translational researchers to discuss the core mechanisms driving inflammation and fibrosis, compare and contrast fibrotic diseases of different organs, discuss the best preclinical models, and debate emerging therapies.

Scholarship Deadline: October 17 2019

Discounted Abstract Deadline: October 17 2019

Abstract Deadline: November 20 2019

Discounted Registration Deadline: December 18 2019

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Pfizer Inc.

Pliant Therapeutics

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1 R13 DK125002-01
Funding for this conference was made possible (in part) by 1 R13 DK125002-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found